Hospital
Methodist Hospital Plainview Texas
Methodist Hospital Plainview Texas was paid $4.00M by Medicaid between Nov 2020 and Dec 2024, across 90 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoMETHODIST HOSPITAL PLAINVIEW TEXAS
PLAINVIEW, TX 79072
PLAINVIEW, TX 79072
33aNPI1073580726assigned 03/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.00M
24GClaims88,192
24DCodes billed90
24AFirst – last monthNov 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#39 of 109
Median peer was paid$1.15M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 612 | $25K | |
| 2021 | 14,441 | $869K | |
| 2022 | 29,983 | $1.67M | |
| 2023 | 30,636 | $986K | |
| 2024incomplete | 12,520 | $449K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 2,563 | 2,370 | $883K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 3,498 | 3,406 | $760K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 18% | 13,938 | 11,948 | $702K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 1,453 | 1,335 | $364K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.4% | 1,865 | 1,833 | $135K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.2% | 7,817 | 7,485 | $128K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.8% | 1,294 | 1,268 | $111K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 8,922 | 7,902 | $78K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.6% | 2,745 | 2,660 | $62K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 875 | 861 | $58K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 903 | 847 | $57K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.4% | 1,041 | 996 | $56K |
78 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 1,283 | $51K |
| 80053 | Comprehensive metabolic panel | <1% | 5,076 | $36K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,467 | $36K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 221 | $34K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,094 | $33K |
| 87081 | <1% | 2,689 | $32K | |
| 86780 | <1% | 1,070 | $31K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,490 | $27K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 325 | $25K |
| 87634 | <1% | 187 | $21K | |
| 81002 | <1% | 2,316 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 191 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 191 | $17K |
| 87420 | <1% | 648 | $16K | |
| 87150 | <1% | 170 | $15K | |
| 87070 | <1% | 651 | $15K | |
| CP007 | <1% | 77 | $14K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 101 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 966 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 581 | $11K |
| 81003 | <1% | 3,019 | $9K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 111 | $9K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 37 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 29 | $7K |
| 84144 | <1% | 87 | $6K | |
| 81025 | <1% | 376 | $5K | |
| 0353U | <1% | 105 | $5K | |
| 87660 | <1% | 86 | $5K | |
| 86803 | <1% | 111 | $4K | |
| 86762 | <1% | 86 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,062 | $4K |
| 86850 | <1% | 118 | $4K | |
| 87510 | <1% | 100 | $4K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 12 | $3K |
| 87480 | <1% | 101 | $3K | |
| 82947 | <1% | 371 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 138 | $3K |
| 87340 | <1% | 102 | $3K | |
| 81001 | <1% | 1,161 | $3K | |
| 73130 | <1% | 17 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 126 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 257 | $2K |
| 80061 | Lipid panel | <1% | 828 | $2K |
| 73560 | <1% | 13 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 44 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 252 | $1K |
| 87077 | <1% | 104 | $1K | |
| 84439 | <1% | 219 | $1K | |
| 84702 | <1% | 31 | $1K | |
| 81000 | <1% | 204 | $1K | |
| 86900 | <1% | 131 | $968.04 | |
| 86901 | <1% | 131 | $951.59 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 61 | $921.92 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 126 | $827.85 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 26 | $806.87 |
| 82950 | <1% | 80 | $805.23 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 73 | $792.84 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 851 | $759.52 |
| 82728 | <1% | 33 | $681.39 | |
| 83735 | <1% | 107 | $631.26 | |
| 82951 | <1% | 29 | $420.59 | |
| 84484 | <1% | 282 | $350.23 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15 | $268.81 |
| 83690 | <1% | 88 | $209.72 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 70 | $201.54 |
| 83880 | <1% | 110 | $153.79 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 13 | $90.56 |
| 82150 | <1% | 19 | $61.70 | |
| 86140 | <1% | 27 | $33.07 | |
| 85610 | <1% | 104 | $26.91 | |
| 85380 | <1% | 12 | $13.94 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 426 | $0.04 |
| A9270 | Non-covered item or service | 0% | 259 | $0.00 |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 13 | $0.00 |
| 83605 | 0% | 54 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 12 | $0.00 |
| 80164 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.